Medicare Enrolled
Dr. Bhadresh Shah, M.D.
Pulmonary Disease · Sugar Land, TX
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Shah from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shah?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Shah
Dr. Bhadresh Shah is a pulmonary disease specialist in Sugar Land, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Shah performed 5,315 Medicare services across 3,829 unique beneficiaries.
Between the years covered by Open Payments, Dr. Shah received a total of $5,407 from 29 pharmaceutical and/or device companies across 201 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Shah is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 4% volume in TX
$5,407 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,315
Medicare services
Top 4% in TX for pulmonary disease
3,829
Unique beneficiaries
$81
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~266 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,125 | $92 | $236 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
958 | $65 | $159 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
432 | $40 | $175 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
423 | $40 | $176 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
393 | $61 | $158 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
328 | $91 | $226 |
| Airflow rate measurement test A test that measures the rate of airflow. This procedure assesses how quickly air moves. |
237 | $29 | $89 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
203 | $29 | $138 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
164 | $30 | $67 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
162 | $71 | $77 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
143 | $78 | $238 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
125 | $132 | $441 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
106 | $120 | $363 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
92 | $11 | $55 |
| Sleep study with continuous airway pressure, age 6+ A sleep study conducted in a sleep lab that monitors breathing and other body functions while administering continuous airway pressure. This test is performed on patients aged 6 years or older. |
90 | $480 | $1,903 |
| Sleep study in sleep lab (age 6+) An overnight test conducted in a sleep laboratory to monitor sleep patterns and bodily functions in patients aged 6 years or older. |
84 | $455 | $1,728 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
68 | $4 | $15 |
| Pneumonia vaccine administration This procedure involves the injection of a vaccine to protect against pneumococcal disease. It is administered by a healthcare provider. |
46 | $29 | $55 |
| Pneumococcal conjugate vaccine (PCV20) An intramuscular injection of the 20-valent pneumococcal conjugate vaccine. It is used to protect against diseases caused by Streptococcus pneumoniae bacteria. |
44 | $276 | $594 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
29 | $137 | $316 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
28 | $163 | $603 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
24 | $100 | $301 |
| Inhaled albuterol and ipratropium bromide via DME Administration of FDA-approved albuterol and ipratropium bromide medication through durable medical equipment. |
11 | $0 | $1 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$5,407
Total received (2018-2024)
Avg $772/year across 7 years
Top 33% in TX for pulmonary disease
29
Companies
201
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,350 (43.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,096 (38.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$961 (17.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$187
2023
$570
2022
$255
2021
$2,737
2020
$907
2019
$370
2018
$381
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$2,598
GlaxoSmithKline, LLC.
$887
Mylan Specialty L.P.
$722
Insmed, Inc.
$193
CSL Behring
$121
Takeda Pharmaceuticals U.S.A., Inc.
$111
Eisai Inc.
$110
Allergan Inc.
$85
Inogen, Inc.
$71
Sunovion Pharmaceuticals Inc.
$68
PFIZER INC.
$68
SANOFI PASTEUR INC.
$41
Teva Pharmaceuticals USA, Inc.
$41
Philips Electronics North America Corporation
$36
Hikma Pharmaceuticals USA
$25
Genentech USA, Inc.
$20
Mallinckrodt Hospital Products Inc.
$20
Regeneron Healthcare Solutions, Inc.
$20
Vanda Pharmaceuticals Inc.
$20
Pulmonx Corporation
$19
GENZYME CORPORATION
$19
Optinose US, Inc.
$18
Circassia Pharmaceuticals Inc
$18
Tactile Systems Technology Inc
$17
Paratek Pharmaceuticals, Inc.
$16
Shionogi Inc
$13
IDORSIA PHARMACEUTICALS US INC
$13
Pinnacle Biologics, Inc
$12
United Therapeutics Corporation
$5
Top 3 companies account for 77.8% of total payments
Associated products mentioned in payments ›
ACTHAR · ANORO · ARALAST · AREXVY · AVYCAZ · AirDuo Digihaler · Arikayce · BREO · BREZTRI · BROVANA · CHANTIX · DUPIXENT · Dayvigo · ELIQUIS · Esbriet · FARXIGA · FASENRA · FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE · Fetroja · Flexitouch Plus · GLASSIA · Hetlioz · IMFINZI · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · InogenOne · LONHALA MAGNAIR · NUCALA · NUZYRA · ORENITRAM · PREVNAR 20 · Photofrin · Pulmonx Endobronchial Valve EBV · QUVIVIQ · Respiratoriy Care Undiv · Ryaltris · TRELEGY ELLIPTA · TUDORZA PRESSAIR · Wellcentive Undiv · Xhance · Yupelri · Zemaira
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (44%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $102 per 100 Medicare services performed
Geographic Context
Pulmonary diseases within 10 mi
108
Per 100K population
12.6
County median income
$113,409
Nearest hospital
HOUSTON METHODIST SUGARLAND HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Shah is a clinical cardiology specialist, with above-average Medicare volume (top 4% in TX), with consulting-driven industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Shah experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Shah performed 1,125 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Shah receive payments from pharmaceutical companies?
Yes. Dr. Shah received a total of $5,407 from 29 companies across 201 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shah's costs compare to other pulmonary diseases in Sugar Land?
Dr. Shah's average Medicare payment per service is $81. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shah) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Sugar Land
Browse pulmonary diseases in Sugar Land ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in TX
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in TX
Which TX pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Mylan Specialty L.P. Payments to Doctors
See all physicians who received payments from Mylan Specialty L.P.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology